市場調査レポート
商品コード
1125994
EXSERVAN:薬剤の考察と市場予測 (2032年)EXSERVAN Drug Insight and Market Forecast - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
EXSERVAN:薬剤の考察と市場予測 (2032年) |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
EXSERVAN (旧名AQST-117) は、筋萎縮性側索硬化症の治療に使われるリルゾールの経口フィルムです。EXSERVANは、舌の上に置く薄いフィルムで構成されています。この溶解性経口フィルムは、1日2回、水なしで服用できるため、錠剤や液体を飲み込むことが困難な患者でも簡単に服用することができます。EXSERVANは、水や飲み込む筋肉を使わずに服用できるため、錠剤や液剤などの従来の薬物療法に代わる手軽な薬物療法を提供することができます。米国FDAから規制当局の承認を受けた後、Aquestive TherapeuticsはEXSERVANのEMA承認プロセスに入っています 。
当レポートでは、筋萎縮性側索硬化症の治療薬の一種であるEXSERVANの市場構造・動向について分析し、製品の概要 (用法・容量、作用機序など) や関連規制、製品開発・治験の進行状況、主要7ヶ国 (米国、欧州5ヶ国 (ドイツ、フランス、イタリア、スペイン、英国)、日本) の市場規模の動向見通し (2022~2032年)、市場の競争状態・SWOT分析、他の治療薬との競合状態、今後の市場成長の可能性などを調査・考察しております。
"EXSERVAN Drug Insight and Market Forecast - 2032" report provides comprehensive insights about EXSERVAN for Amyotrophic Lateral Sclerosis in seven major markets. A detailed picture of the EXSERVAN for Amyotrophic Lateral Sclerosis in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the EXSERVAN for Amyotrophic Lateral Sclerosis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the EXSERVAN market forecast analysis for Amyotrophic Lateral Sclerosis in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Amyotrophic Lateral Sclerosis.
EXSERVAN, formerly known as AQST-117 is an oral Riluzole film used to treat Amyotrophic Lateral Sclerosis. EXSERVAN consists of a thin film that is placed on the tongue, utilizes the company's "PharmFilm" technology. The dissolving oral film can be taken twice daily without water, making it easier for patients who have difficulty swallowing pills or liquids. EXSERVAN offers an easy alternative to tablets, liquids, or other traditional forms of medication as it can be taken without water or the need to use swallowing muscles. After receiving a regulatory nod from the US FDA, Aquestive Therapeutics is in the EMA approval process for EXSERVAN (Muscular Dystrophy Association, 2019).
The recommended dosage for EXSERVAN is 50 mg taken orally twice daily. EXSERVAN should be taken at least 1 hour before or 2 hours after a meal. (US FDA, 2020)
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
EXSERVAN Analytical Perspective by DelveInsight
This report provides a detailed market assessment of EXSERVAN for Amyotrophic lateral sclerosis in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.
The report provides the clinical trials information of EXSERVAN for Amyotrophic Lateral Sclerosis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions